Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Gene Therapy Market: By Vector Type, By Disease Type, and Region Forecast 2019-2030
Gene Therapy Market size was valued at US$ 8.9 billion in 2023 and is poised to grow at a CAGR of 21.6% from 2024-2030. A gene is a functioning hereditary unit of life that contains instructions for performing a certain function. Gene therapy is the advanced treatment for cancer, chronic disease, infectious disease, and blood diseases. On the basis of vector type, the Adeno-associated Virus Vector segment is anticipated to hold the major market value in the forecasting market because the Adeno-associated virus (AAV) is a non-enveloped virus that may be modified to transfer DNA to target cells. It has attracted a lot of interest recently, especially in clinical-stage experimental therapy techniques.
One of the safest gene therapy technologies so far has been the capacity to manufacture recombinant AAV particles devoid of viral genes and DNA sequences of interest for diverse therapeutic purposes. Adeno-associated Virus vectors are used more frequently than other traditional methodologies due to their ease of use. Considering these benefits, the adeno-associated virus segment is anticipated to grow in the forecasting period. Globally, growth in the prevalence of chronic diseases such as cancer, rare genetic disorders, and others is driving the market growth. Moreover, increased government funding, ethical acceptability of gene therapy for cancer treatment, and favorable reimbursement policies contribute to the market growth in the future.
Study Period
2024-2030Base Year
2023CAGR
21.6%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
Increase in the R&D expenditure for the development of novel therapeutics has a substantial impact on the global gene therapy market. Market players are aiming to develop a gene therapy platform with a strategy focused on establishing a transformational portfolio through in-house capabilities and enhancing those capabilities through strategic collaborations, expansion of R&D activities, potential licensing, merger, and acquisition activities. For instance, In March 2021, Elevate Bio, one of the leading biotech companies focused on gene-based therapies, raised USD 525 million to advance its cell and gene therapy technologies.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 8.9 billion |
Market CAGR |
21.6% |
By Vector Type |
|
By Disease Type |
|
By Region |
|
Download Free Sample Report
The global gene therapy market size was valued at US$ 8.9 billion in 2023 and is projected to grow at a significant CAGR of 21.6% from 2024 to 2030.
Amgen Inc., Bristol-Myers Squibb., Orchard Therapeutics, Gilead Sciences, Novartis AG
Asia-Pacific is the fastest-growing region for Gene Therapy Market
1. Executive Summary |
2. Global Gene Therapy Market Introduction |
2.1. Global Gene Therapy Market – Taxonomy |
2.2. Global Gene Therapy Market –Definitions |
2.2.1. By Vector Type |
2.2.2. By Disease Type |
2.2.3. By Region |
3. Global Gene Therapy Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Current Trends |
3.5. Global Gene Therapy Market Dynamic Factors - Impact Analysis |
3.6. Mergers, Acquisitions, and Collaborations |
4. Global Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Gene Therapy Market, By Vector Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Adeno Virus Vector |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Adeno-associated Virus Vector |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Lentiviral Vector |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Retroviral Vector |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Herpes Virus Vector |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6. Global Gene Therapy Market, By Disease Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1. Oncological Disorders |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cardiovascular Diseases |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Lentiviral Vector |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Retroviral Vector |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Herpes Virus Vector |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7. Global Gene Therapy Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Latin America |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. MEA |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Global Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Region, 2024 - 2030 |
8. North America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
8.1.1. Adeno Virus Vector |
8.1.2. Adeno-associated Virus Vector |
8.1.3. Lentiviral Vector |
8.1.4. Retroviral Vector |
8.1.5. Herpes Virus Vector |
8.1.6. Others |
8.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.2.1. Oncological Disorders |
8.2.2. Cardiovascular Diseases |
8.2.3. Neurological Disorders |
8.2.4. Infectious disease |
8.2.5. Rare Diseases |
8.2.6. Others |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
8.3.1. United States |
8.3.2. Canada |
8.4. North America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
8.5. North America Gene Therapy Market Dynamics – Trends |
9. Europe Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Adeno Virus Vector |
9.1.2. Adeno-associated Virus Vector |
9.1.3. Lentiviral Vector |
9.1.4. Retroviral Vector |
9.1.5. Herpes Virus Vector |
9.1.6. Others |
9.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Oncological Disorders |
9.2.2. Cardiovascular Diseases |
9.2.3. Neurological Disorders |
9.2.4. Infectious disease |
9.2.5. Rare Diseases |
9.2.6. Others |
9.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. UK |
9.3.2. Germany |
9.3.3. France |
9.3.4. Italy |
9.3.5. Spain |
9.3.6. Rest of Europe |
9.4. Europe Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
9.5. Europe Gene Therapy Market Dynamics – Trends |
10. Asia Pacific Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Adeno Virus Vector |
10.1.2. Adeno-associated Virus Vector |
10.1.3. Lentiviral Vector |
10.1.4. Retroviral Vector |
10.1.5. Herpes Virus Vector |
10.1.6. Others |
10.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Oncological Disorders |
10.2.2. Cardiovascular Diseases |
10.2.3. Neurological Disorders |
10.2.4. Infectious disease |
10.2.5. Rare Diseases |
10.2.6. Others |
10.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. China |
10.3.2. India |
10.3.3. ANZ |
10.3.4. Japan |
10.3.5. Rest of APAC |
10.4. Asia Pacific Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
10.5. Asia Pacific Gene Therapy Market Dynamics – Trends |
11. Latin America Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Adeno Virus Vector |
11.1.2. Adeno-associated Virus Vector |
11.1.3. Lentiviral Vector |
11.1.4. Retroviral Vector |
11.1.5. Herpes Virus Vector |
11.1.6. Others |
11.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Oncological Disorders |
11.2.2. Cardiovascular Diseases |
11.2.3. Neurological Disorders |
11.2.4. Infectious disease |
11.2.5. Rare Diseases |
11.2.6. Others |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Brazil |
11.3.2. Mexico |
11.3.3. Argentina |
11.3.4. Rest of LA |
11.4. Latin America Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
11.5. Latin America Gene Therapy Market Dynamics – Trends |
12. MEA Gene Therapy Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. Vector Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) and Volume (Units), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Adeno Virus Vector |
12.1.2. Adeno-associated Virus Vector |
12.1.3. Lentiviral Vector |
12.1.4. Retroviral Vector |
12.1.5. Herpes Virus Vector |
12.1.6. Others |
12.2. Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Oncological Disorders |
12.2.2. Cardiovascular Diseases |
12.2.3. Neurological Disorders |
12.2.4. Infectious disease |
12.2.5. Rare Diseases |
12.2.6. Others |
12.3. Country Level Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. GCC Countries |
12.3.2. South Africa |
12.3.3. Rest of MEA |
12.4. MEA Gene Therapy Market - Opportunity Analysis Index, By Vector Type, Disease Type, and Country, 2016-2027 |
12.5. MEA Gene Therapy Market Dynamics – Trends |
13. Competition Landscape |
13.1. Strategic Dashboard of Top Market Players |
13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
13.2.1. Bristol-Myers Squibb Company |
13.2.2. Sanofi SA |
13.2.3. F. Hoffmann-La Roche Ltd. |
13.2.4. Novartis AG |
13.2.5. Shire Plc |
13.2.6. Gilead Lifesciences, Inc. |
13.2.7. REGENXBIO Inc. |
13.2.8. Amgen, Inc. |
13.2.9. Celgene Corporation |
13.2.10. UniQure N.V. |
13.2.11. Orchard Therapeutics Plc |
14. Research Methodology |
15. Key Assumptions and Acronyms |
Key Market Players